News | May 18, 2021
Remdesivir production increased to 119 lakh vials per month
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The facility is expected to be completed in 2024
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
Acquisition of A&C expands Aceto’s Western manufacturing footprint
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection
Subscribe To Our Newsletter & Stay Updated
